Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (81-90 of 238) with videos related to

Pageof 24
Sort By:
Hepatology (Baltimore, Md.)|July 29, 2018
Retinoic Acid Receptor-β Is Downregulated in Hepatocellular Carcinoma and Cirrhosis and Its Expression Inhibits Myosin-Driven Activation and Durotaxis in Hepatic Stellate CellsErnesto Cortes, Dariusz Lachowski, Alistair Rice, et al.
Neuroendocrinology|February 26, 2020
Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine TumoursDavid J Pinato, Anu Vallipuram, Joanne S Evans, et al.
Oncotarget|June 1, 2016
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative studyDavid J Pinato, Tadaaki Arizumi, Jeong Won Jang, et al.
Frontiers in Immunology|February 1, 2024
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogramAgnese Losurdo, Angelo Dipasquale, Laura Giordano, et al.
Oncotarget|February 18, 2017
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenibJessica Howell, David J Pinato, Ramya Ramaswami, et al.
Cancer Treatment Reviews|August 31, 2025
Interpreting immunogenicity in oncology clinical trialsPeter R Galle, Martin Reck, David J Pinato, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 10, 2020
Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using <sup>18</sup>F-Fluorothymidine PETRohini Sharma, Marianna Inglese, Suraiya Dubash, et al.
JHEP Reports : Innovation in Hepatology|April 7, 2023
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trialsClaudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 17, 2024
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver MalignancyAndrew S Kennedy, Daniel B Brown, Marwan Fakih, et al.
Gut|February 27, 2025
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studiesCiro Celsa, Grazia Pennisi, Adele Tulone, et al.
Pageof 24

Showing results (81-90 of 238) with videos related to

Sort By:
Pageof 24
Hepatology (Baltimore, Md.)|July 29, 2018
Retinoic Acid Receptor-β Is Downregulated in Hepatocellular Carcinoma and Cirrhosis and Its Expression Inhibits Myosin-Driven Activation and Durotaxis in Hepatic Stellate CellsErnesto Cortes, Dariusz Lachowski, Alistair Rice, et al.
Neuroendocrinology|February 26, 2020
Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine TumoursDavid J Pinato, Anu Vallipuram, Joanne S Evans, et al.
Oncotarget|June 1, 2016
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative studyDavid J Pinato, Tadaaki Arizumi, Jeong Won Jang, et al.
Frontiers in Immunology|February 1, 2024
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogramAgnese Losurdo, Angelo Dipasquale, Laura Giordano, et al.
Oncotarget|February 18, 2017
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenibJessica Howell, David J Pinato, Ramya Ramaswami, et al.
Cancer Treatment Reviews|August 31, 2025
Interpreting immunogenicity in oncology clinical trialsPeter R Galle, Martin Reck, David J Pinato, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 10, 2020
Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using <sup>18</sup>F-Fluorothymidine PETRohini Sharma, Marianna Inglese, Suraiya Dubash, et al.
JHEP Reports : Innovation in Hepatology|April 7, 2023
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trialsClaudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 17, 2024
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver MalignancyAndrew S Kennedy, Daniel B Brown, Marwan Fakih, et al.
Gut|February 27, 2025
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studiesCiro Celsa, Grazia Pennisi, Adele Tulone, et al.
Pageof 24